25 participants with radiopaque stones (Calcium Oxalate) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)

25 participants with radiopaque stones (Calcium Oxalate) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8)

25 participants with radiolucent stones (Uric acid) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)

25 participants with radiolucent stones (Uric acid) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 7.0-7.2

Renal Stones

AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma

AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)

Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)

Potassium Sodium Hydrogen Citrate

Mohamed Salim Ahmed Al-Marhoon

Treatment of Renal Stones With Frankincense (Luban)

Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial

The participants intolerance of the treatment or development of side effects that are not known complications of the presence of stones or new adverse reactions

Senior Consultant Urological Surgeon and Head of Urology

Sultan Qaboos University

Renal Neoplasm With Metastasis

Response Evaluation Criteria in Solid Tumors

Aarhus University Hospital

Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CT

Response Evaluation Criteria in Metastatic Renal Cell Carcinoma: Improved Assessment of Response and Progression by Spectral-CT

PFS is the time from the initiation of therapy and until progressive disease or death, whichever comes first, assessed up to 60 months. If a patient does not progress, PFS will be censored at the time of last follow-up - assessed up to 60 months.

Overall survival is the time between the first day of treatment and the date of death or last follow-up - assessed up to 60 months.

Response will be categorized according to the criteria from RECIST 1.1: complete response, partial response, stable disease and progressive disease - assessed up to 60 months.

Frede Donskov

Consultant, Associate Professor

University of Aarhus

185 megabecquerel (MBq) of Ioflupane I-123 (DaTSCAN) will be administered IV to patients with suspected renal cell carcinoma, at a single occasion and followed by SPECT-analysis 5h after injection.The images from the DaTSCAN investigation will be analyzed and anatomically compared to CT-scan from the same the patient. Any adverse effects during the study will be reported.
This is a exploratory open single arm trial, including a small number of patients with suspected disseminated renal cell carcinoma.

185 megabecquerel (MBq) of Ioflupane I-123 will be administered IV to patients with suspected renal cell carcinoma, at a single occasion and followed by SPECT-analysis 5h after injection.
Ioflupane I123: 185 MBq ioflupane I133 will be administered at one single occasion to the study subjects

Experimental Group

Sex: Female, Male

Race and Ethnicity Not Collected

Region of Enrollment

Pathological assessment of renal cell carcinoma (RCC) subtype was determined following surgical resection of the tumour. This occurs after DaTSCAN analysis.
Classified as ccRCC=clear cell renal cell carcinoma or non-ccRCC=all other subtypes of kidney cancer

RCC subtype

The primary endpoint is to investigate if tumors detected with CT display Ioflupane positivity in patients with verified clear cell renal cell carcinoma (ccRCC). Ioflupane signal was considered positive when intensity was >3 times background signal in anatomic position identified as a lesion by CT-scan

185 megabecquerel (MBq) of Ioflupane I-123 will be administered IV to patients with suspected renal cell carcinoma, at a single occasion and followed by SPECT-analysis 5h after injection.
Ioflupane I123: 185 MBq ioflupane I123 will be administered at one single occasion to the study subjects

Number of Participants That Display Ioflupane-positivity in Tumors Detected Via CT-scan

Ioflupane I123 displays no positive signal in lesions identifies by CT in patients with tumors classified as non-clear cell renal cell carcinoma

Number of Participants Diagnosed With Non-ccRCC That Display Ioflupane I123-negativity in Tumors Detected Via CT-scan

Overall Study

Professor Håkan Axelson

Clear Cell Renal Cell Carcinoma

185 MBq ioflupane I123 will be administered at one single occasion to the study subjects A one time dose of DaTSCAN is given via intravenous injection of 185 MBq Ioflupane (I123) .
The patient takes potassium iodine tablets prior to the DatSCAN injection to protect the thyroid gland. At the time of the DaTSCAN examination, the patient is injected intravenously at slow rate with 185MBq DaTSCAN solution.

kidney neoplasms/kalium

Treatment of Renal Stones With Frankincense (Luban)

Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CT

Diagnostic Imaging for Clear Cell Renal Cell Carcinoma

Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird